Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS Negl Trop Dis ; 10(1): e0004285, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26745276

ABSTRACT

The dynamics of regulatory T cells in the course of Trypanosoma cruzi infection is still debated. We previously demonstrated that acute murine T. cruzi infection results in an impaired peripheral CD4+Foxp3+ T cell differentiation due to the acquisition of an abnormal Th1-like phenotype and altered functional features, negatively impacting on the course of infection. Moreover, T. cruzi infection induces an intense thymic atrophy. As known, the thymus is the primary lymphoid organ in which thymic-derived regulatory T cells, known as tTregs, differentiate. Considering the lack of available data about the effect of T. cruzi infection upon tTregs, we examined tTreg dynamics during the course of disease. We confirmed that T. cruzi infection induces a marked loss of tTreg cell number associated to cell precursor exhaustion, partially avoided by glucocorticoid ablation- and IL-2 survival factor depletion. At the same time, tTregs accumulate within the CD4 single-positive compartment, exhibiting an increased Ki-67/Annexin V ratio compared to controls. Moreover, tTregs enhance after the infection the expression of signature markers (CD25, CD62L and GITR) and they also display alterations in the expression of migration-associated molecules (α chains of VLAs and chemokine receptors) such as functional fibronectin-driven migratory disturbance. Taken together, we provide data demonstrating profound alterations in tTreg compartment during acute murine T. cruzi infection, denoting that their homeostasis is significantly affected. The evident loss of tTreg cell number may compromise the composition of tTreg peripheral pool, and such sustained alteration over time may be partially related to the immune dysregulation observed in the chronic phase of the disease.


Subject(s)
Chagas Disease/pathology , T-Lymphocytes, Regulatory/immunology , Thymus Gland/pathology , Trypanosoma cruzi/immunology , Animals , Annexin A5/analysis , Atrophy/pathology , Disease Models, Animal , Humans , Ki-67 Antigen/analysis , Male , Mice, Inbred BALB C , Mice, Inbred C57BL
2.
Protein Pept Lett ; 22(5): 432-42, 2015.
Article in English | MEDLINE | ID: mdl-25731591

ABSTRACT

The "A proliferation inducing ligand" protein (APRIL) is a cytokine over-expressed in many transformed and tumoral cells acting onto two distinct receptors of the Tumoral Necrosis Factor B cell maturation antigen (BCMA) and the transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). We herein describe, through a detailed computational approach, the molecular interactions between TACI and its ligands APRIL and another structurally similar protein called B-cell activating factor (BAFF) by means of molecular dynamics. Dynamical analysis suggests R84 and D85 residues from TACI as possible mutation candidates, yielding increased affinity between TACI and APRIL. The association of computational simulations, site directed mutagenesis and peptide design could be a powerful tool, driving to better in vitro experiments. Our results contribute to the elucidation of APRIL signaling and help clarify the effects of blocking interaction between APRIL and its receptors through the use of particular peptides.


Subject(s)
B-Cell Activating Factor/metabolism , Peptides/pharmacology , Transmembrane Activator and CAML Interactor Protein/metabolism , Tumor Necrosis Factor Ligand Superfamily Member 13/antagonists & inhibitors , Tumor Necrosis Factor Ligand Superfamily Member 13/metabolism , Amino Acid Sequence , Animals , B-Cell Activating Factor/chemistry , Drug Design , Humans , Immunosorbent Techniques , Ligands , Mice , Molecular Dynamics Simulation , Molecular Sequence Data , Peptides/chemistry , Protein Binding/drug effects , Protein Interaction Maps/drug effects , Transmembrane Activator and CAML Interactor Protein/chemistry , Tumor Necrosis Factor Ligand Superfamily Member 13/chemistry
3.
Cytokine ; 75(2): 228-33, 2015 Oct.
Article in English | MEDLINE | ID: mdl-25481649

ABSTRACT

Rheumatoid Arthritis (RA) is a chronic inflammatory disease affecting synovial joints. Tumor necrosis factor (TNF) α is a key component of RA pathogenesis and blocking this cytokine is the most common strategy to treat the disease. Though TNFα blockers are very efficient, one third of the RA patients are unresponsive or present side effects. Therefore, the development of novel therapeutic approaches is required. RA pathogenesis is characterized by the hyperplasia of the synovium, closely associated to the pseudo-tumoral expansion of fibroblast-like synoviocytes (FLS), which invade and destroy the joint structure. Hence, depletion of RA FLS has been proposed as an alternative therapeutic strategy. The TNF family member Fas ligand (FasL) was reported to trigger apoptosis in FLS of arthritic joints by binding to its receptor Fas and therefore suggested as a promising candidate for targeting the hyperplastic synovial tissue. However, this cytokine is pleiotropic and recent data from the literature indicate that Fas activation might have a disease-promoting role in RA by promoting cell proliferation. Therefore, a FasL-based therapy for RA requires careful evaluation before being applied. In this review we aim to overview what is known about the apoptotic and non-apoptotic effects of Fas/FasL system and discuss its relevance in RA.


Subject(s)
Apoptosis/physiology , Arthritis, Rheumatoid/drug therapy , Fas Ligand Protein/metabolism , Synovial Membrane/pathology , fas Receptor/metabolism , Apoptosis/drug effects , Enzyme Activation/drug effects , Fas Ligand Protein/agonists , Fibroblasts/metabolism , Humans , Signal Transduction/immunology , Synovial Membrane/cytology , Tumor Necrosis Factor-alpha/metabolism , fas Receptor/agonists
4.
Arthritis Rheumatol ; 66(12): 3289-99, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25078097

ABSTRACT

OBJECTIVE: Injection of agonistic anti-Fas antibody has been shown to decrease disease symptoms in mouse models of arthritis. Additionally, membrane-bound FasL (mFasL) has been shown to induce cell death in fibroblast-like synoviocytes (FLS) from rheumatoid arthritis (RA) patients. However, levels of soluble FasL (sFasL) are increased in the joints of RA patients and have been associated with disease severity, indicating that mFasL and sFasL play opposing roles in RA. The purpose of this study was to analyze the effects of FasL on RA FLS responses. METHODS: The responses of FLS from RA and osteoarthritis (OA) patients to soluble and oligomeric FasL, the latter mimicking mFasL, were analyzed by fluorescence-activated cell sorting and proliferation assays, using 3 different FasL variants. The signaling pathways that trigger FasL responses were characterized by Western blotting. RESULTS: We found that mFasL and sFasL have distinct roles in RA FLS. Crosslinked FasL preferentially induced apoptosis, whereas sFasL stimulated proliferation. Moreover, sFasL activated several signaling pathways in RA FLS, such as ERK-1/2, phosphatidylinositol 3-kinase, caspase 8, and JNK, with a prominent role of JNK, since only the blockade of this pathway rendered FLS more susceptible to FasL-induced apoptosis. Crosslinked FasL induced apoptosis in FLS from OA patients, but sFasL failed to stimulate their proliferation. CONCLUSION: Our findings suggest that sFasL is a disease promoter in RA, a finding consistent with previous reports describing a tumor-promoting role of FasL. Therefore, blocking of sFasL could be a therapeutic strategy for RA.


Subject(s)
Apoptosis/physiology , Arthritis, Rheumatoid/metabolism , Cell Proliferation/physiology , Fas Ligand Protein/metabolism , Fibroblasts/metabolism , Synovial Membrane/metabolism , Adult , Aged , Apoptosis/drug effects , Cell Proliferation/drug effects , Cells, Cultured , Fas Ligand Protein/drug effects , Female , Fibroblasts/drug effects , Flow Cytometry , Humans , MAP Kinase Signaling System/drug effects , MAP Kinase Signaling System/physiology , Male , Middle Aged , Osteoarthritis/metabolism , Phosphatidylinositol 3-Kinases/drug effects , Phosphatidylinositol 3-Kinases/physiology , Synovial Membrane/cytology , Synovial Membrane/drug effects
5.
Neuroimmunomodulation ; 18(5): 328-38, 2011.
Article in English | MEDLINE | ID: mdl-21952685

ABSTRACT

During immune response to infectious agents, the host develops an inflammatory response which could fail to eliminate the pathogen or may become dysregulated. In this case, the ongoing response acquires a new status and turns out to be detrimental. The same elements taking part in the establishment and regulation of the inflammatory response (cytokines, chemokines, regulatory T cells and counteracting compounds like glucocorticoids) may also mediate harmful effects. Thymic disturbances seen during Trypanosoma cruzi (T. cruzi) infection fit well with this conceptual framework. After infection, this organ suffers a severe atrophy due to apoptosis-induced thymocyte exhaustion, mainly affecting the immature double-positive (DP) CD4+CD8+ population. Thymus cellularity depletion, which occurs in the absence of main immunological mediators involved in anti-T. cruzi defense, seems to be linked to a systemic cytokine/hormonal imbalance, involving a dysregulated increase in Tumor Necrosis Factor alpha (TNF-α) and corticosterone hormone levels. Additionally, we have found an anomalous exit of potentially autoimmune DP cells to the periphery, in parallel to a shrinkage in the compartment of natural regulatory T cells. In this context, our data clearly point to the view that the thymus is a target organ of T. cruzi infection. Preserved thymus may be essential for the development of an effective immune response against T. cruzi, but this organ is severely affected by a dysregulated circuit of proinflammatory cytokines and glucocorticoids. Also, the alterations observed in the DP population might have potential implications for the autoimmune component of human Chagas disease.


Subject(s)
Allergy and Immunology , Chagas Disease , Endocrinology , Thymus Gland/immunology , Thymus Gland/metabolism , Antigens, CD/metabolism , Chagas Disease/immunology , Chagas Disease/metabolism , Chagas Disease/pathology , Cytokines/metabolism , Glucocorticoids/metabolism , Humans , Thymus Gland/pathology
6.
Arthritis Res Ther ; 13(4): 232, 2011 Jul 26.
Article in English | MEDLINE | ID: mdl-21861866

ABSTRACT

Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting synovial joints. Therapies blocking tumor necrosis factor-alpha (TNFα) are now routinely used in the management of RA. However, a significant number of patients with RA do not respond or develop resistance to anti-TNF therapies, and the participation of other cytokines in RA pathogenesis has been reported as well. Lymphotoxin alpha (LTα) is the closest homolog to TNFα and has been implicated in inflammation and autoimmunity since its original description in 1968. In spite of that, little is known about the role of LTα in RA or the potential of blocking this cytokine as an alternative therapeutic approach. In this review, we aim to summarize the general features of LTα and what is currently known about its participation in RA.


Subject(s)
Arthritis, Rheumatoid/immunology , Lymphotoxin-alpha/immunology , Animals , Humans
7.
Arthritis Rheum ; 63(4): 904-13, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21305500

ABSTRACT

OBJECTIVE: Results of studies in mice suggest a protective role for TRAIL in arthritis. The aim of this study was to investigate the role of TRAIL in patients with rheumatoid arthritis (RA). METHODS: In the present study, we compared RA fibroblast-like synoviocytes (FLS) that were resistant or sensitive to TRAIL-induced apoptosis and the expression of TRAIL receptors in these cells, and also investigated the clinical features of the patients from whom the FLS were derived. Furthermore, we evaluated the levels of TRAIL and its soluble decoy receptor osteoprotegerin (OPG) in patients with RA, patients with osteoarthritis (OA), and patients with spondylarthritis (SpA). RESULTS: Sensitivity to TRAIL-induced apoptosis varied in FLS from different patients, and the severity of disease in patients with RA was inversely correlated with the susceptibility of their FLS to TRAIL-induced apoptosis. TRAIL-sensitive cells expressed significantly lower levels of TRAILR-1, and silencing of TRAILR-1 increased TRAIL-induced apoptosis in RA FLS. TRAIL levels were elevated in the arthritic joints of patients with established RA, and TRAIL levels in the synovial fluid of these patients were elevated compared with levels in the synovial fluid of patients with OA or SpA. At baseline, a low OPG-to-TRAIL ratio in the sera of patients with early RA was associated with a better evolution of disease activity, but high serum levels of TRAIL at followup were associated with joint damage. CONCLUSION: These findings suggest that TRAIL has a dual role in RA, and that the resistance of RA FLS to TRAIL-induced apoptosis is associated with a disease-promoting activity of TRAIL in RA.


Subject(s)
Arthritis, Rheumatoid/physiopathology , Fibroblasts/pathology , Synovial Membrane/pathology , Synovial Membrane/physiopathology , TNF-Related Apoptosis-Inducing Ligand/physiology , Adolescent , Adult , Aged , Aged, 80 and over , Apoptosis/physiology , Arthritis, Rheumatoid/metabolism , Arthritis, Rheumatoid/pathology , Female , Fibroblasts/metabolism , Humans , Interleukin-6/metabolism , Interleukin-8/metabolism , Male , Middle Aged , Osteoarthritis/metabolism , Osteoarthritis/pathology , Osteoarthritis/physiopathology , Osteoprotegerin/metabolism , Severity of Illness Index , Spondylarthritis/metabolism , Spondylarthritis/pathology , Spondylarthritis/physiopathology , Synovial Membrane/metabolism , Young Adult
8.
Cytokine ; 53(2): 207-14, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21111629

ABSTRACT

OBJECTIVE: TNFα plays a crucial role in rheumatoid arthritis (RA) by stimulating fibroblast-like synoviocytes (FLS). Lymphotoxin α (LTα) is a pro-inflammatory cytokine with significant homology to TNFα. We compared the effects of both cytokines on cultured RA FLS. METHODS: Receptor expression on RA FLS was analyzed by FACS. Cells were stimulated with LTα or TNFα and proliferation was measured by [3H]thymidine incorporation and secretion of inflammatory cytokines and metalloproteinase 3 by ELISA. Activation of MAP kinases and Akt was analyzed by Western blotting. Nuclear translocation of NFκB was visualized by immunofluorescence. RESULTS: 60-80% and 30-50% of the RA FLS tested expressed TNF receptors I and II, respectively, and 70-75% expressed HVEM. LTα induced RA FLS proliferation at the same level of TNFα, which was blocked by etanercept. Both LTα and TNFα induced activation of MAP kinases ERK1/2 and p38 as well as Akt. 95-98% of FLS showed nuclear translocation of NFκB after stimulation with either cytokines. LTα and TNFα were potent to induce secretion of IL-6, IL-8 and metalloproteinase 3 in FLS. CONCLUSION: LTα is as effective as TNFα in stimulating RA FLS. Blocking both cytokines might allow a better control of inflammation and synovial proliferation in RA.


Subject(s)
Arthritis, Rheumatoid/pathology , Cytokines/metabolism , Fibroblasts/metabolism , Inflammation Mediators/metabolism , Lymphotoxin-alpha/pharmacology , Synovial Fluid/cytology , Cell Nucleus/drug effects , Cell Nucleus/metabolism , Cell Proliferation/drug effects , Enzyme Activation/drug effects , Etanercept , Extracellular Signal-Regulated MAP Kinases/metabolism , Fibroblasts/drug effects , Fibroblasts/enzymology , Fibroblasts/pathology , Humans , Immunoglobulin G/pharmacology , Matrix Metalloproteinase 3/metabolism , NF-kappa B/metabolism , Protein Kinase Inhibitors/pharmacology , Protein Transport/drug effects , Proto-Oncogene Proteins c-akt/metabolism , Receptors, Tumor Necrosis Factor , Receptors, Tumor Necrosis Factor, Member 14/metabolism , Receptors, Tumor Necrosis Factor, Type I/metabolism , Receptors, Tumor Necrosis Factor, Type II/metabolism , Synovial Fluid/drug effects , p38 Mitogen-Activated Protein Kinases/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...